Document is current
Any future updates will be listed below
-
Authors
Sass, Frederike https://orcid.org/0000-0002-6144-7661
Ma, Tao https://orcid.org/0000-0003-2570-9449
Ekberg, Jeppe H.
Kirigiti, Melissa
Ureña, Mario G.
Dollet, Lucile
Brown, Jenny M. https://orcid.org/0000-0002-5072-4491
Basse, Astrid L. https://orcid.org/0000-0002-6532-9232
Yacawych, Warren T.
Burm, Hayley B.
Andersen, Mette K. https://orcid.org/0000-0001-8227-1469
Nielsen, Thomas S. https://orcid.org/0000-0002-9457-8000
Tomlinson, Abigail J.
Dmytiyeva, Oksana
Christensen, Dan P.
Bader, Lindsay
Vo, Camilla T.
Wang, Yaxu
Rausch, Dylan M. https://orcid.org/0000-0001-6095-4891
Kristensen, Cecilie K.
Gestal-Mato, María https://orcid.org/0000-0002-5096-2609
In het Panhuis, Wietse https://orcid.org/0000-0002-4394-6387
Sjøberg, Kim A.
Kernodle, Stace
Petersen, Jacob E. https://orcid.org/0000-0002-2116-1626
Pavlovskyi, Artem
Sandhu, Manbir
Moltke, Ida
Jørgensen, Marit E. https://orcid.org/0000-0001-8356-5565
Albrechtsen, Anders https://orcid.org/0000-0001-7306-031X
Grarup, Niels https://orcid.org/0000-0001-5526-1070
Babu, M. Madan https://orcid.org/0000-0003-0556-6196
Rensen, Patrick C. N. https://orcid.org/0000-0002-8455-4988
Kooijman, Sander https://orcid.org/0000-0002-0014-5571
Seeley, Randy J. https://orcid.org/0000-0002-3721-5625
Worthmann, Anna
Heeren, Joerg https://orcid.org/0000-0002-5647-1034
Pers, Tune H. https://orcid.org/0000-0003-0207-4831
Hansen, Torben https://orcid.org/0000-0001-8748-3831
Gustafsson, Magnus B. F.
Tang-Christensen, Mads
Kilpeläinen, Tuomas O. https://orcid.org/0000-0002-8349-3028
Myers, Martin G. Jr
Kievit, Paul
Schwartz, Thue W. https://orcid.org/0000-0002-0261-6904
Hansen, Jakob B.
Gerhart-Hines, Zachary https://orcid.org/0000-0003-2981-4991
- License Information
-
More Information
Article History
Received: 16 February 2023
Accepted: 11 October 2024
First Online: 13 November 2024
Competing interests
: T.M., J.H.E., J.B.H., D.P.C., M.B.F.G., M.T.-C., T.W.S. and Z.G.-H. work or have worked in some capacity for Embark Laboratories ApS, a company developing therapeutics for the treatment of T2D and obesity. P.K. is a consultant for Embark Laboratories ApS. The use of and chemical composition for NK2R agonists are patented by the University of Copenhagen and Embark Laboratories ApS, respectively. R.J.S. has received research support from Novo Nordisk, Fractyl, AstraZeneca, Congruence Therapeutics, Eli Lilly, Bullfrog AI, Glycsend Therapeutics and Amgen. R.J.S. has served as a paid consultant for Novo Nordisk, Eli Lilly, CinRx, Fractyl, Structure Therapeutics, Crinetics and Congruence Therapeutics. R.J.S. has equity in Calibrate, Rewind and Levator Therapeutics. The other authors declare no competing interests.
